Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21097658 | 0.87 | BCL9 (0.56) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL21097204 | 0.87 | BCL9 (0.56) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL12375535 | 0.87 | BCL9 (0.56) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL8915013 | 0.85 | BCL9 (0.50) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL21058129 | 0.84 | BCL9 (0.57) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL21058130 | 0.84 | BCL9 (0.57) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL16203199 | 0.84 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL30209699 | 0.84 | BCL9 (0.54) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL21058146 | 0.84 | BCL9 (0.57) | HTR2ABCL9CTNNB1GAAMGLL | |
| SCHEMBL9846640 | 0.84 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367711-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-20 | — | — | US | disclosed |
| US-8252825-B2 | Angiotensin II receptor antagonists | NICOX (IT) | 2012-08-28 | — | — | US | disclosed |
| US-8207208-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| US-20110065765-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
| EP-2291076-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-7880014-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100311800-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2010-12-09 | — | — | US | disclosed |
| US-20100273845-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-10-28 | — | — | US | disclosed |
| US-20080194660-A1 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| WO-2008076246-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-6992076-B2 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050272710-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| EP-1343805-A4 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | XENOPORT INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1343805-A1 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | Xenoport, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020151529-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | XENOPORT, INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002028881-A1 | BILE-ACID DERIVED COMPOUNDS FOR PROVIDING SUSTAINED SYSTEMIC CONCENTRATIONS OF DRUGS AFTER ORAL ADMINISTRATION | XENOPORT, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| US-5684018-A | Acyloxyisopropyl carbamates as prodrugs for amine drugs | MERCK & CO., INC. (US) | 1997-11-04 | — | — | US | disclosed |
| WO-1996018605-A1 | ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, AGT | HTR2A 464/4885BCL9 4339/4885CTNNB1 4671/4885 |
| US-20100311800-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR2, AGTR1, AGT | HTR2A 138/4885BCL9 4631/4885CTNNB1 4708/4885 |
| US-20080194660-A1 | Angiotensin II receptor antagonists | AGTR1, AGTR2, REN | HTR2A 335/4885BCL9 3742/4885CTNNB1 3903/4885 |
| US-20020151529-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | SLC10A2, SLC10A1, ABCB11 | HTR2A 2906/4885BCL9 2071/4885CTNNB1 3882/4885 |
| US-20100273845-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR2, AGTR1, REN | HTR2A 331/4885BCL9 4343/4885CTNNB1 3639/4885 |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | HTR2A 395/4885BCL9 4234/4885CTNNB1 4543/4885 |
| US-20110065765-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | HTR2A 419/4885BCL9 4192/4885CTNNB1 4632/4885 |
| US-20050272710-A1 | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration | SLC10A2, SLC10A1, ABCB11 | HTR2A 2906/4885BCL9 2071/4885CTNNB1 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.